TITLE:
Gemtuzumab ozogamicin in the treatment of adult acute myeloid leukemia
AUTHORS:
Hiroko Tsunemine, Takayuki Takahashi
KEYWORDS:
Gemtuzumab Ozogamicin; Acute Myeloid Leukemia; Acute Promyelocytic Leukemia; Monotherapy; Combination Chemotherapy; Sinusoidal Obstruction Syndrome; Veno-Occlusive Disease
JOURNAL NAME:
Health,
Vol.5 No.5A,
May
27,
2013
ABSTRACT: Gemtuzumab ozogamicin (GO) is a humanized
anti-CD33 monoclonal antibody conjugated to a derivative
of an antitumor antibiotic, calicheamicin. GO was approved for the treatment
of relapsed acute myeloid leukemia (AML) in the United States (US) in 2000.
However, GO was withdrawn from the US
market in June 2010, because a large-scale clinical trial failed to show
additive or synergistic effects with conventional chemotherapy for newly
diagnosed AML. GO is currently available
only in Japan. However, several large clinical studies have demonstrated
beneficial effects of GO when added to chemotherapy for AML in recent years;
therefore, reconsideration of GO availability is gaining attention. Therefore,
the role and efficacy of GO as monotherapy or in combination therapy for de novo or relapsed AML should be
positively investigated.